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of 1320 colorectal cancers with Consensus Molecular
Subgroup (CMS) data
Anne Trinh1, Claudia Lädrach2, Heather E. Dawson2, Sanne ten Hoorn3, Peter J. K. Kuppen4, Marlies S. Reimers4, Miriam Koopman5,
Cornelis J. A. Punt6, Alessandro Lugli2, Louis Vermeulen3 and Inti Zlobec1
BACKGROUND: Tumour budding is an important prognostic factor in colorectal cancer (CRC). Molecular proﬁling of tumour buds
suggests (partial) epithelial–mesenchymal transition and cancer stem-cell phenotype, similarly described in the “mesenchymal”
Consensus Molecular Subtype 4 (CMS4), which identiﬁes a particularly poor prognostic subgroup. Here, we determine the
association of tumour budding with CMS classiﬁcation, prognosis, and response to therapy.
METHODS: AMC-AJCCII-90 cohort (n= 76, stage II) was evaluated for peritumoural budding on H&E slides. LUMC (n= 270, stage
I–IV), CAIRO (n= 504, metastatic CRC) and CAIRO2 (n= 472, metastatic CRC) cohorts were investigated for intratumoural budding
using pan-cytokeratin-stained tissue microarrays. Budding was scored as count/area, then classiﬁed as <5 or ≥5 buds. For all
cohorts, CMS classiﬁcations were available (gene-expression/immunohistochemistry-based classiﬁers).
RESULTS: High (≥5) budding predicted a worse outcome in multivariate analysis in AMC-AJCCII-90 (p= 0.018), LUMC (p < 0.0001),
and CAIRO (p= 0.03), and in CAIRO2 (continuous variable, p= 0.02). Tumour budding counts were higher in CMS4 compared to
epithelial CMS2/3 cancers (p < 0.01, all), and associated with KRAS/BRAF mutations (p < 0.01, AMC-AJCCII-90, CAIRO, CAIRO2).
CONCLUSION: Tumour budding is an adverse prognostic factor across all CRC stages and is associated with the mesenchymal
CMS4 phenotype. KRAS/BRAF mutations are strongly correlated with tumour budding suggesting their involvement in the
regulation of this process.
British Journal of Cancer (2018) 119:1244–1251; https://doi.org/10.1038/s41416-018-0230-7
INTRODUCTION
Tumour budding in colorectal cancer is now established as a
strong, independent prognostic factor.1 It is associated with
advanced stage of disease as well as shorter disease-free survival
(DFS) and overall survival (OS).2 The International Tumour Budding
Consensus Conference (ITBCC) underlined the importance of this
prognostic parameter and, as a consequence, this histologic
feature has recently been added to both the 8th edition of the
TNM staging manual and CAP guidelines.
Tumour budding is described as the presence of single tumour
cells or small tumour cell clusters dissociated from the main
tumour body. The frequency of tumour budding is approximately
40% but varies signiﬁcantly in the reported literature due to
methodological and scoring differences.2 Although typically
described as occurring at the invasive front (peritumoural
budding, PTB) and detected in surgical resections of colorectal
cancer, the presence of tumour budding within the main tumour
body (intratumoural budding, ITB) has also been described.1 This
latter observation has highlighted a clinically important role for
tumour budding in the pre-operative management of patients
with rectal cancers since the presence of ITB can also be detected
in pre-treatment biopsies.
Tumour buds are thought to have the properties of cells
undergoing an epithelial–mesenchymal transition (EMT), or a
partial-EMT state.3 In fact, laser capture microdissection studies in
both colorectal cancers and oral squamous cell carcinomas show
that tumour buds over-express EMT-related genes such as ZEB1,
ZEB2, DES, TGFB3, and VIM in comparison to the main tumour
mass.4 At the protein level, frequent loss of E-cadherin and β-
catenin from the membrane can be observed, not only in
colorectal cancer but also in pancreatic ductal adenocarcinomas
and oral squamous cell carcinoma, indicating that activation of
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both WNT and TGF-β signalling may be occurring.4–6 In addition to
reduced proliferation and apoptosis in these cells, tumour buds
are reported as having an overexpression of genes involved in
extracellular matrix degradation, invasion, and migration and may
co-express both vimentin (a mesenchymal marker) and cytoker-
atin (an epithelial marker), again in line with a transitory EMT-like
phenotype.3,7
In 2015, Guinney, following a large collaborative effort to which
we have contributed, published a widely adapted comprehensive
classiﬁcation of colorectal cancer and identiﬁed four distinct
subtypes.8 The ﬁrst subtype, CMS1, included predominantly
hypermethylated cancers with microsatellite instability (MSI),
BRAF mutation, and a rich immune cell inﬁltrate. The second
subtype, CMS2, was identiﬁed as the canonical colorectal cancer
type with WNT pathway activation and chromosomal instability,
while CMS3 encompassed tumours with profound metabolic
deregulation and frequent KRAS mutations. The fourth group
called “mesenchymal”, is found in 23% of all cases and
characterised by stromal inﬁltration, overexpression of genes
involved in EMT and TGF-β activation, matrix remodeling, and
angiogenesis among others. Prognostically, the CMS4 group
exhibited the worst OS and DFS demonstrating an urgent clinical
need to develop therapies that would be effective for this subtype.
In addition, we recently established an immunohistochemistry-
based tissue microarray classiﬁer based on ﬁve protein markers
(CDX2, FRMD6, HTR2B, ZEB1, and pan-cytokeratin) to determine
patients’ CMS in cohorts where gene-expression proﬁling
is unavailable.9 The accuracy of the classiﬁer was found to be
87% in discriminating between the epithelial (CMS2/3) and
mesenchymal (CMS4) groups. Moreover, this classiﬁer distin-
guished patients with the worst OS and DFS, validating the
CMS4 subtype.
Taken together, the molecular and prognostic proﬁle of
CMS4 patients is reminiscent of a high-grade tumour budding
phenotype, and we speculated an association between tumour
cell budding and the mesenchymal colorectal cancer subtype.
To test this hypothesis, we investigated the association between
tumour budding, CMS groups, and prognosis in four cohorts
including patients from a series of stage II patients (AMC-AJCCII-
90), a stage I–IV cohort (LUMC), and two randomised clinical trials
of metastatic colorectal cancer (CAIRO and CAIRO2).
MATERIAL AND METHODS
Patient cohorts
Four independent patient cohorts were used in this study: the
AMC-AJCCII-90 series collected between 1997 and 2006,10 LUMC
collected between 1991 and 2001 following surgical interven-
tion,11 the CAIRO trial enrolling patients between 2003 and
2004 (Trial Registration ID: NCT00312000),12 and the CAIRO2
trial enrolling patients between 2005 and 2006 (Trial Registration
ID: NCT00208546)13 series. The CAIRO trial assesses the efﬁcacy
of sequential compared to combination treatment with capecita-
bine, irinotecan, and oxaliplatin. The CAIRO2 trial assesses the
added beneﬁt of the anti-EGFR agent cetuximab to a regimen of
capecitabine, oxaliplatin, and bevacizumab.
Patient sample specimens and clinical information were
obtained and processed using IRB-approved protocols. The
gold standard CMS classiﬁcation based on microarray (Affymetrix)
gene expression data was available for the AMC-AJCCII-90
cohort, while LUMC, CAIRO, and CAIRO2 were classiﬁed into
CMS groups using an IHC-based tissue microarray classiﬁer
described in ref. 9
Patients were excluded from this study due to the following
criteria: (i) insufﬁcient patient material for tissue microarray or H&E
slide construction; (ii) poor quality or missing tissue microarray
cores; and/or (iii) incomplete clinical records, as summarised in
Supplementary Figure 1.
Tissue microarray construction
Three 0.6 mm cores were included in the construction of the tissue
microarray for the LUMC cohort whereas for CAIRO and CAIRO2
cohorts, tissues were mounted onto single-punch tissue micro-
arrays of 2.0 mm in diameter. Tissue microarray construction is
described in detail in Trinh et al.9 Slides were sectioned at 4 µm
and immunohistochemistry for cytokeratin AE1/AE3 (1:500; cat
M351529-2 Aligent) was performed. After a secondary incubation
with anti-rabbit-HRP or anti-mouse-HRP (Powervision), staining
was developed using DAB+ Chromogen (Dako) and counter-
stained with haematoxylin. For the AMC-AJCCII-90 cohort, whole
slide tumour sections were cut at 4 µm and after preparation and
antigen retrieval (sodium citrate buffer, pH 6.0) of the formalin
ﬁxed parafﬁn embedded (FFPE) sections they were stained with
haematoxylin (Mayer) and eosin Y (Sigma).
KRAS/BRAF mutation detection
KRAS and BRAF mutation status was determined in the AMC-
AJCCII-90 series and CAIRO2 cohort by PCR of the V600E site in
BRAF and codons 12 and 13 of KRAS; and validated by Sanger
sequencing of exon 2 of KRAS and exon 15 in BRAF as previously
reported.13–15 BRAF status in the CAIRO cohort was determined by
high resolution melting sequencing analysis16 and KRAS status
was determined by next-generation sequencing using the TruSeq
Amplicon Cancer Panel.17 KRAS and BRAF mutation data were not
available for the LUMC cohort.
BRAF and KRAS mutation testing was performed in the CAIRO,
CAIRO2 cohorts only after the completion of these trials for
scientiﬁc purposes, for example following the discovery that
patients with mutations in the KRAS/BRAF axis are refractory to
anti-EGFR therapy, and for comparison to other putative (genetic)
biomarkers of therapy response.18
Quantifying tumour budding
Peritumoural budding (PTB) using ITBCC criteria. Tumour budding
was assessed in the AMC-AJCCII-90 cohort according to recom-
mendations of the ITBCC on scanned haematoxylin and eosin
(H&E) stained slides.1 One representative slide of tumour per case
was available for scoring. Tumour buds were counted in a single
circular hotspot measuring 0.785mm2 at the invasive front. Both
tumour budding count and tumour budding category, namely BD1
(0–4 buds/0.785mm2), BD2 (5–9 buds/0.785 mm2), and BD3 (≥10
buds/0.785mm2) were recorded. In three cases, tumour budding
could not be assessed as the selected slide contained only
mucinous and/or signet ring cell formations. Representative areas
of the three ITBCC budding categories are shown in Fig. 1a–c.
Intratumoural budding (ITB). Pan-cytokeratin-stained tissue
microarrays were used to assess tumour budding in the LUMC,
CAIRO, and CAIRO2 cohorts by means of ITB. ITB was deﬁned as
one single cell or a cell cluster of up to ﬁve tumour cells each
containing a distinct nucleus and surrounded by tumour
stroma.2,19 Areas of necrosis were avoided. Punches with more
than 40% missing area were removed from the analysis. For
patients with multiple cores, the average number of buds across
all viable samples was used. Representative pan-cytokeratin
stained tissue microarray punches showing low- and high-grade
tumour budding are shown in Fig. 1d–f.
Statistics
Descriptive statistics were performed for tumour budding on all
cohorts. ITB was assessed both as a categorical variable (using a
threshold of 5) and a continuous variable represented in the
log10 scale. Differences in the number of tumour buds by CMS
groups or KRAS/BRAF mutation were analysed using the Wilcox-
on’s Rank Sum Test. OS and DFS analyses were performed using
univariate and multivariate Cox proportional hazards models
accounting for age, stage, and sex with 60 months (5-year) follow-
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up, after which samples were right censored. Differences in
survival were expressed as hazard ratios (HR) with 95% conﬁdence
intervals. Signiﬁcance was tested using the log-rank test. Survival
curves were constructed using the Kaplan–Meier method. All
p-values < 0.05 were considered statistically signiﬁcant.
RESULTS
Summary of patient cohorts and tumour budding counts
The association of tumour budding with prognosis and CMS
subtypes was performed using four different patient cohorts of
various TNM stages and using different methods.
The AMC-AJCCII-90 series (n= 76) included only patients with
stage II disease. PTB was evaluated on H&E slides according to the
ITBCC guidelines (number of buds followed by categorisation
into BD1 < 5 buds versus BD2+ BD3 ≥ 5 buds), in a hotspot of
0.785mm2. The average budding count was six buds (std ±8),
with a median of three buds per tumour. Each tumour in the
AMC-AJCCII-90 cohort was previously classiﬁed into one of the
four CMS subtypes based on gene expression proﬁles.8
The LUMC cohort included patients (n= 268) with TNM stages
I–IV. Tumours were mounted onto 0.6 mm diameter, multi-
core tissue microarrays. ITB was assessed after pan-cytokeratin
immunohistochemistry. The average ITB count was four (std ±9)
buds per punch, with a median of zero buds per tumour. Results
from the IHC-based tissue microarray classiﬁer were used to
determine the CMS of each case.
In the CAIRO (n= 504) and CAIRO2 (n= 472) cohorts, all
patients had metastatic cancers (stage IV). Colorectal cancers from
both trials were included onto 2.0 mm diameter tissue microarrays
stained for pan-cytokeratin. Average ITB budding counts were 30
(std ±40) and 44 buds (std ±72) in CAIRO and CAIRO2, respectively,
with median counts of 15 and 18. The IHC-based tissue microarray
classiﬁer results were used to assign CMS groups.9
Patient characteristics of all four cohorts are provided in Table 1.
Prognostic effect of tumour budding
The association of tumour budding with DFS (LUMC, AMC-AJCCII-
90) or OS (CAIRO, CAIRO2) was investigated in two ways. The ﬁrst
analysis was based on dichotomizing budding counts into <5 and
≥5 buds for PTB in the AMC-AJCCII-90 cohort and a proposed cut-
off from the literature for ITB for the remaining tissue microarray
cohorts,19 while the second was based on the raw tumour
budding counts in each cohort.
High tumour budding (>5 buds) is associated with poor disease-free
and overall survival. Since the survival time of patients with BD2
and BD3 cancers was similar and due to the small number of
patients in each BD group, we combined BD2+ BD3 into a single
category for analysis. High tumour budding was associated with
poor DFS in both the AMC-AJCCII-90 and LUMC cohorts. PTB in the
AMC-AJCCII-90 cohort shows a worse DFS in patients with high-
grade budding although the difference is not statistically signiﬁcant
(HR: 2.39 (0.89–6.38), p= 0.074; Fig. 2a). However, adjusting for
age, sex, and T stage, a signiﬁcant worse and independent effect
on outcome in this cohort for patients with high-grade budding
was observed (3.53 (1.15–10.83), p= 0.02, Fig. 3a).
Similarly, univariate analysis of high- versus low-grade ITB in the
LUMC cohort demonstrated a signiﬁcantly worse DFS (HR: 2.15
(1.49–3.09); p < 0.0001; Fig. 2b), which again was maintained in
multivariable analysis adjusting for sex, age, and TNM stage (HR:
2.30 (1.56–3.38), p≪ 0.0001) (Fig. 3a). In fact, patients with high-
grade budding exhibited a 2.3 times greater relative risk of
recurrence as compared to patients with low-grade budding,
indicating that tumour budding is an independent prognostic
factor in this cohort.
However, the relation between ITB and disease outcome was
variable in the metastatic setting. In the CAIRO cohort, treatment
arms were combined and the association between budding OS
time was analysed. OS time was signiﬁcantly worse in patients
with high-grade budding within the primary tumour in univariate
analysis (HR: 1.34 (1.09–1.65); p= 0.0049; Fig. 2c), with a median
time to death decreasing from 21.7 (18.6–25.9) months to 16.2
(14.6–18.2) months. In a multivariate analysis that included age,
sex, and treatment arm, tumour budding maintained its effect
on prognosis, namely, patients with high-grade budding had a
worse outcome compared to patients with low-grade budding
tumours (HR: 1.36 (1.11–1.68), p= 0.03 (Fig. 3a)). In CAIRO2, no
association between tumour budding and survival could be found
(Figs. 2d, 3a).
Modeling tumour budding as a continuous variable. Evaluating
the number of tumour buds and DFS or OS, a signiﬁcant
association was found between a higher number of tumour
a b c
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Fig. 1 Representative images of tumour budding on H&E slides depicting ITBCC classiﬁcations. a BD1 (0–4 buds/0.785 mm2), b BD2 (5–9 buds/
0.785mm2), and c BD3 (≥10 buds/0.785mm2), and pan-cytokeratin-stained slides representing (d) absence, e low-grade budding (<5 buds),
and f high-grade budding (≥5 buds)
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buds and worse outcome in all four cohorts in Cox models
adjusted for age, sex, and TNM stage (Fig. 3b).
The AMC-AJCCII-90 cohort showed a trend of higher budding
counts associated with worse DFS in a multivariate model
adjusted for age, sex, and T stage (HR: 3.1 (0.92–10.52), p= 0.04).
Similarly, for the LUMC cohort, a higher number of tumour buds
was found to have prognostic signiﬁcance when analysed in a
multivariable model adjusting for sex and TNM stage (HR: 1.97
(1.35–2.87); p≪ 0.0001).
A similar association between budding and OS in metastatic
colorectal cancer was observed in the CAIRO cohort in multivariate
analysis (HR: 1.27 (1.09–1.48); p= 0.02) adjusting for sex and age.
In CAIRO2, a signiﬁcant impact of tumour budding on OS was
found in multivariate analysis taking into account age and sex
(HR: 1.15 (0.98–1.36), p= 0.02) (Fig. 3b).
Predictive effect of tumour budding to different treatment
We sought to determine whether ITB had any predictive value in
the metastatic setting through the retrospective analysis of the
CAIRO and CAIRO2 clinical trials.
The CAIRO clinical trial assessed the efﬁcacy of sequential versus
combination chemotherapy involving capecitabine, irinotecan,
and oxaliplatin. Stratifying patients by treatment regimen in
the CAIRO cohort showed that a high-grade tumour budding
phenotype was found to correlate with worse prognosis both in
the sequential treatment arm (Arm A) and the combination arm
(Arm B) in univariate analysis using a cut-off of 5 (Arm A: HR= 1.4
(1.06–1.87), p= 0.02; Arm B: HR: 1.34 (0.99–1.81), p= 0.06)
(Supplemental Figure 2A). However, modeling budding as a
continuous variable shows a prognostic effect only in Arm A
(Arm A: HR= 1.38 (1.1–1.72), p= 0.04; Arm B: HR= 1.20
(0.97–1.47), p= 0.23) (Supplemental Figure 2B). These data
suggest that ITB is an unfavourable prognostic factor in both
treatment arms, but does not have predictive value.
Similarly, we stratiﬁed the CAIRO2 cohort according to whether
patients were treated with the anti-EGFR agent cetuximab in
addition to a baseline regimen of capecitabine, oxaliplatin, and
bevacizumab. Patients with cetuximab therapy did not differ
in prognosis when tumours were stratiﬁed by budding status
using a cut-off of 5 (Supplemental Figure 2C), but showed a
trend of increased budding counts associated with poorer
prognosis in the cetuximab arm in multivariate analysis including
sex and age (HR: 1.25 (0.98–1.58), p= 0.1) (Supplemental
Figure 2D). This association was however lost when taking
into account KRAS and BRAF status (HR budding: 1.21
(0.83–1.75), p= 0.15). These results indicate that tumour budding
is not a predictive factor of response to anti-EGFR therapy in RAS/
RAF wild-type patients.
Association with CMS and molecular features
We next determined the association of tumour budding
within CMS subgroups, focusing on the difference in tumour
buds between the epithelial-like CMS2/3 subtypes versus the
mesenchymal-like CMS4 group.
Table 1. Summary of patient characteristics
Feature CAIRO LUMC CAIRO2 AMC-AJCCII-90
No. of patients 504 270 472 76
Sample information TMA or slide TMA TMA TMA Whole slide
Core diameter 2 mm 0.6mm 2mm –
Staining CK CK CK H&E
Age (years) 62.8
(41–78)
65.4
(39.3–86.4)
61.3
(40.3–76)
–
Sex F 181 135 197 40
M 322 135 275 36
Stage 1 0 43 0 0
2 0 99 0 76
3 0 75 0 0
4 504 50 472 0
Event status None 61 91 104 60
Yes 443 179 368 16
Treatment arma A 252 – 243 –
B 252 – 229 –
Mutational information
MSI MSI-H 12 29 8 23
MSS/MSI-L 423 189 464 53
KRAS/BRAF mut 174 – 218 31
wt 139 – 227 45
CMS classiﬁcation
CMS classiﬁer IHC IHC IHC GeneExp
CMS available 401 214 340 76
Subtype CMS2/3 247 96 162 35
CMS4 142 89 170 15
TMA tissue microarray, CK pan-cytokeratin, H&E haematoxylin and eosin, MSI microsatellite instability, CMS Consensus Molecular Subtype aTreatment arms:
CAIRO—sequential (Arm A) versus combination (Arm B) capecitabine, irinotecan, and oxaliplatin. CAIRO2—capecitabine, oxaliplatin, and bevacizumab (Arm A)
with cetuximab (Arm B)
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In all four cohorts, there was a signiﬁcantly greater number of
tumour buds identiﬁed in the CMS4 subtype compared to CMS2/3,
namely in AMC-AJCCII-90 (mean: 11.5 versus 4.4 buds; p= 0.005),
LUMC (mean: 3.84 versus 2.1 buds; p= 0.01), CAIRO (mean: 41.4
versus 23.9 buds; p « 0.0001), and CAIRO2 (mean: 59.6 versus 32.5
buds; p= 0.007) (Fig. 4).
Given that budding was not shown to be predictive for
cetuximab therapy, we also sought to determine whether this
could be due to an association between budding and mutational
status in the KRAS/BRAF axis.
Interestingly, a signiﬁcant correlation was found between
a higher number of tumour buds and KRAS mutation in all
three cohorts (AMC-AJCCII-90 p= 0.002; CAIRO2 p= 0.003; CAIRO
p= 0.04, Wilcoxon Rank Sum Test). Additionally, higher ITB was
observed in BRAF mutant metastatic samples (CAIRO p= 0.0002;
CAIRO2 p= 0.01, Wilcoxon Rank Sum Test) (Fig. 5).
DISCUSSION
In this study, we investigated the prognostic effect of tumour
budding on 1320 patients with colorectal cancers across various
cohorts, including two randomised clinical trials for metastatic
patients. In addition, we evaluated the association of tumour
budding with the CMS in order to test the hypothesis that the
“mesenchymal-like” subtype (CMS4), which shares similarities in
molecular proﬁle with tumour buds and their microenvironment,
would be associated with a high-grade tumour budding phenotype.
We validated the prognostic effect of tumour budding
independent of age, stage, and sex in three of the four cohorts.
It is known that a higher number of tumour buds is correlated
with worse survival in patients with colorectal cancer. Evidence
suggests that regardless of scoring method, the presence of
tumour budding is associated with advanced disease stage and
worse clinical outcome.2,20,21 There are, however, several new
elements in this study. Firstly, we can show using a randomised
clinical trial of metastatic patients (CAIRO) that tumour budding is
indeed prognostic in this setting. Secondly, we could validate the
newly established ITBCC criteria for the scoring of tumour budding
on H&E slides in a stage II cohort with DFS as the endpoint.
The cutoff proposed by the ITBCC (BD1, BD2, BD3) is based on the
scoring method already integrated into the Japanese Guidelines
for the reporting of colorectal cancer. A recent retrospective study
by Oh and colleagues pooled results from more than 4000
Japanese patients from all stages and validated the effect of high-
grade budding on worse OS and DFS.22 However, in contrast to
this study, Oh and colleagues evaluated budding using a three-
tiered system (equivalent to BD1, BD2, and BD3) and only found
an association between BD1/2 versus BD3 and outcome. Thirdly,
this study underlines the value of ITB as a prognostic factor in both
the metastatic and mixed stage cohorts, since counts were
evaluated on tissue microarrays constructed without speciﬁc
regard to the localisation (centre/invasion front) within the
tumour. Although ITB rather than PTB could be evaluated in
three of the four cohorts here, both ITB and PTB counts are highly
AMC-AJCCII-90a b
c dCARIO (mCRC) CARIO2 (mCRC)
LUMC
1.00
0.75
D
is
ea
se
-fr
ee
 s
ur
vi
va
l p
ro
ba
bi
lity
O
ve
ra
ll 
su
rv
iva
l p
ro
ba
bi
lity
D
is
ea
se
-fr
ee
 s
ur
vi
va
l p
ro
ba
bi
lity
0.50
0.25
0.00
1.00
0.75
0.50
0.25
0.00
O
ve
ra
ll 
su
rv
iva
l p
ro
ba
bi
lity
1.00
0.75
0.50
0.25
0.00
1.00
0.75
0.50
0.25
0.00
HR: 2.39 (0.89–6.38)
log rank P = 0.074
HR: 1.34 (1.09–1.65)
log rank P = 0.0049
HR: 1.10 (0.87–1.39)
log rank P = 0.043
HR: 2.15 (1.49–3.06)
log rank P < 0.0001
0 10 20 30
Time (months)Number at risk
No. of Buds <5
No. of Buds 5
Number at risk
No. of Buds <5
No. of Buds 5
Buds 5
Buds <5
Buds 5
Buds <5
Buds 5
Buds <5
Buds 5
Buds <5
40 50 60 0 10 20 30
Time (months)
40 50 60
211 180 150 138 131 121 114
59 37 27 23 19 18 17
50 46 40 36 30 20 14
26 21 16 13 7 4 2
0 10 20 30
Time (months)Number at risk
No. of Buds <5
No. of Buds 5
40 50 60
151 118 79 49 18 4 0
353 252 139 68 30 8 1
0 10 20 30
Time (months)Number at risk
No. of Buds <5
No. of Buds 5
40 50 60
130 102 71 36 21 12 1
341 274 176 94 43 17 0
Fig. 2 Kaplan–Meier curves representing survival time differences across the different cohorts with a cut-off of ﬁve tumour buds for low- or
high-grade budding. a AMC-AJCCII-90, b LUMC, c CAIRO, and d CAIRO2. Differences in survival are reported as univariate hazard ratios with
95% conﬁdence intervals, and p values were calculated using the log-rank method
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correlated when ITB is present.19 It should be mentioned that
differences in methodology regarding ITB counts have been
described. Lugli et al. used CK22 staining and counted buds in
multi-punch tissue microarrays, taking the maximum number of
buds as the ﬁnal count, whereas in this study AE1/AE3 staining
was performed and the average number of buds was taken.
Unfortunately, false-negatives, namely cases which exhibit PTB but
no ITB, may occur and this could be a part of the explanation for
the lack of correlation between tumour budding and outcome in
the CAIRO2 cohort in multivariable analysis. In addition, the
distribution of budding counts in this cohort suggests that a cutoff
of ﬁve buds is not optimal for this setting, as we demonstrated
a prognostic effect when ITB was assessed on a continuous
scale. Despite the different composition of cohorts and the
various methods used for assessing tumour budding including
tissue microarrays, whole slides as well as H&E or pan-cytokeratin,
tumour budding is validated here as an independent prognostic
factor.
Additionally, we evaluated the association between tumour
budding and the CMS taxonomy. For the AMC-AJCCII-90 series,
assignment of CMS was performed using gene expression,8 while
the IHC-based classiﬁer was used to assign CMS classes to the
tumours from the CAIRO, CAIRO2, and LUMC cohorts.9 Indeed,
we found in all four cohorts a signiﬁcantly greater number of
tumour buds in the CMS4 compared to CMS2/3. The CMS4
group represents a set of tumours with upregulated expression of
mesenchymal and EMT-related genes, as well as those involved
with TGF-β signalling, matrix remodeling, stemness, wound
healing, and angiogenesis.8 These tumours have both low content
of immune cells and low-expression of immune cell activation
markers. These ﬁndings are in line with the described proﬁles of
tumour buds, or more precisely the microenvironment of tumour
buds.3 RNA- or DNA-based studies to date have attempted
to analyse molecular proﬁles of tumour buds.4,6,23 These proﬁles
include mesenchymal, EMT, and cancer stem-like genes consistent
with the patterns of the CMS4 group. As they appear as single cells
or small cell clusters, it is challenging to perform experiments
directly on tumour buds, hence one criticism of this approach is
that the expression patterns observed are not strictly from the
buds themselves but very likely also from the adjacent stromal
microenvironment. It is also known that proteins such as TWIST1
and SNAI1 are only rarely expressed in tumour buds, but are
profusely found in cancer-associated ﬁbroblasts in regions of high-
grade budding.5,24 We believe that the CMS4 group contains high-
grade tumour budding cancers and that the molecular proﬁle of
these CMS4 tumours reﬂects not only the tumour cells themselves,
but also the stromal microenvironment in which they reside.
Finally, we observed that the extent of tumour budding was
signiﬁcantly greater in cancers with KRAS and BRAF mutations.
The relationship between KRAS mutation and tumour budding
has previously been reported.25–27 Jang and colleagues found
that 21/34 colorectal cancers with high-grade tumour budding
also had mutations in KRAS.28 They encourage the assessment
of tumour budding for patients receiving anti-EGFR therapy. Our
group has previously investigated progression-free survival in
patients treated with anti-EGFR therapy based on tumour budding
status.29 We showed not only that tumour budding led to worse
clinical outcome in cetuximab-treated patients but that there
was an added beneﬁt to KRAS mutation status in terms of
identifying possible non-responders. In this study however, we
could not show a predictive effect of tumour budding speciﬁc
to anti-EGFR therapy or chemotherapy regimen, but patients
with high-grade budding had worse OS in both sequential or
combined chemotherapy groups. Furthermore, Cho et al. present
RAS destabilisation as a potential approach for preventing
metastatic progression.30 The RAS protein was shown to be
signiﬁcantly more abundant in tumour buds than in other cells in
human colorectal cancers. In vitro treatment of KRAS mutated
cell lines with KY011, a compound that destabilises β-catenin
and RAS proteins, prevented spindle cell morphology as well as
E-cadherin loss and vimentin over-expression. Taken together,
these results all point toward KRAS mutation as an element
regulating the tumour budding phenotype, which deserves
exploration in a further study. Of note, KRAS mutations are not
acquired in tumour buds as shown in a next-generation
sequencing study of driver mutations comparing tumour buds
with other regions of the tumour.31
Our study is limited by the use of tissue microarrays for the
assessment of tumour budding, since areas selected for tissue
microarray construction were selected for epithelial-rich regions
rather than targeting regions containing buds. Nonetheless,
we could evaluate ITB in these punches and could still show an
association of tumour budding with outcome, using single punch
2.0 mm cores or 3 × 0.6 mm cores. Secondly, an IHC-based tissue
microarray classiﬁer trained on the AMC-AJCCII-90 cohort had an
accuracy of 87%, which itself introduces a misclassiﬁcation rate
of 13% in discriminating CMS groups in the LUMC, CAIRO, and
CAIRO2 cohorts. On the other hand, our study was complemented
by the AMC-AJCCII-90 cohort, for which gold-standard RNA-based
CMS group assignment was available. Moreover, results from
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all cohorts showed an association between higher number of
tumour buds and the mesenchymal subtype.
To conclude, tumour budding is not only an independent and
adverse prognostic factor in all stages of colorectal cancer, but
is associated with the poor “mesenchymal-like” prognostic group
of the consensus molecular subtypes. We believe that the CMS4
group is enriched for high-grade budding cancers, which is also
underlined by the similar molecular proﬁles associated with
both tumour budding and CMS4 tumours. In addition, KRAS/BRAF
mutation is strongly correlated with tumour budding suggesting
that this molecular change may play a role in regulating the
budding phenotype.
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